DK314688A - Fremgangsmaader til forbedret maalsoegning med antistof, antistoffragmenter, hormoner og andre maalsoegningsmidler samt konjugater deraf - Google Patents
Fremgangsmaader til forbedret maalsoegning med antistof, antistoffragmenter, hormoner og andre maalsoegningsmidler samt konjugater derafInfo
- Publication number
- DK314688A DK314688A DK314688A DK314688A DK314688A DK 314688 A DK314688 A DK 314688A DK 314688 A DK314688 A DK 314688A DK 314688 A DK314688 A DK 314688A DK 314688 A DK314688 A DK 314688A
- Authority
- DK
- Denmark
- Prior art keywords
- antibody
- antibodies
- fragments
- hormones
- peptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91717686A | 1986-10-09 | 1986-10-09 | |
| PCT/US1987/002656 WO1988002594A2 (en) | 1986-10-09 | 1987-10-09 | Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK314688D0 DK314688D0 (da) | 1988-06-09 |
| DK314688A true DK314688A (da) | 1988-08-08 |
Family
ID=25438446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK314688A DK314688A (da) | 1986-10-09 | 1988-06-09 | Fremgangsmaader til forbedret maalsoegning med antistof, antistoffragmenter, hormoner og andre maalsoegningsmidler samt konjugater deraf |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0288520B1 (da) |
| JP (1) | JPH01501476A (da) |
| AT (1) | ATE122894T1 (da) |
| AU (1) | AU616161B2 (da) |
| CA (1) | CA1340312C (da) |
| DE (1) | DE3751319T2 (da) |
| DK (1) | DK314688A (da) |
| WO (1) | WO1988002594A2 (da) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5202252A (en) * | 1982-03-05 | 1993-04-13 | Houston Biotechnology Inc. | Monoclonal antibodies against lens epithelial cells and methods for preventing proliferation of remnant lens epithelial cells after extracapsular extraction |
| US5616122A (en) * | 1986-11-04 | 1997-04-01 | Baylor College Of Medicine | Methods and compositions for preventing secondary cataracts |
| DE68924783T2 (de) * | 1988-09-30 | 1996-03-28 | Neorx Corp | Wässrige additivsysteme, verfahren und polymerteilchen. |
| US5066789A (en) * | 1988-09-30 | 1991-11-19 | Neorx Corporation | Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages |
| FR2639231A1 (fr) * | 1988-11-23 | 1990-05-25 | Merieux Inst | Utilisation de fragments fc d'immunoglobulines g humaines, de peptides analogues du fragment fc, ou d'immunoglobulines g humaines dans l'obtention d'un medicament preparatoire a l'administration chez l'homme, dans un but therapeutique ou de diagnostic, d'anticorps monoclonaux |
| US4986979A (en) * | 1989-03-14 | 1991-01-22 | Neorx Corporation | Imaging tissue sites of inflammation |
| ATE136224T1 (de) * | 1989-09-29 | 1996-04-15 | Neorx Corp | Reduktion der nichtzielspezifischen retention von immunokonjugaten und ihren metaboliten |
| ATE183513T1 (de) | 1993-06-03 | 1999-09-15 | Therapeutic Antibodies Inc | Herstellung von antikörperfragmenten |
| ATE285417T1 (de) | 1995-11-03 | 2005-01-15 | Binding Site Ltd | Herstellung von antikörpern |
| WO2009080831A1 (en) * | 2007-12-26 | 2009-07-02 | Biotest Ag | Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates |
| US9221914B2 (en) | 2007-12-26 | 2015-12-29 | Biotest Ag | Agents targeting CD138 and uses thereof |
| CN101965366B (zh) | 2007-12-26 | 2016-04-27 | 生物测试股份公司 | 靶向cd138的免疫缀合物及其应用 |
| WO2009080832A1 (en) | 2007-12-26 | 2009-07-02 | Biotest Ag | Methods and agents for improving targeting of cd138 expressing tumor cells |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4664911A (en) * | 1983-06-21 | 1987-05-12 | Board Of Regents, University Of Texas System | Immunotoxin conjugates employing toxin B chain moieties |
-
1987
- 1987-10-09 AU AU81587/87A patent/AU616161B2/en not_active Ceased
- 1987-10-09 CA CA000548968A patent/CA1340312C/en not_active Expired - Fee Related
- 1987-10-09 JP JP62506607A patent/JPH01501476A/ja active Pending
- 1987-10-09 AT AT87907199T patent/ATE122894T1/de active
- 1987-10-09 EP EP87907199A patent/EP0288520B1/en not_active Expired - Lifetime
- 1987-10-09 WO PCT/US1987/002656 patent/WO1988002594A2/en not_active Ceased
- 1987-10-09 DE DE3751319T patent/DE3751319T2/de not_active Expired - Lifetime
-
1988
- 1988-06-09 DK DK314688A patent/DK314688A/da not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1988002594A2 (en) | 1988-04-21 |
| CA1340312C (en) | 1999-01-12 |
| ATE122894T1 (de) | 1995-06-15 |
| EP0288520A1 (en) | 1988-11-02 |
| JPH01501476A (ja) | 1989-05-25 |
| AU8158787A (en) | 1988-05-06 |
| DE3751319T2 (de) | 1996-02-29 |
| EP0288520B1 (en) | 1995-05-24 |
| AU616161B2 (en) | 1991-10-24 |
| DE3751319D1 (de) | 1995-06-29 |
| DK314688D0 (da) | 1988-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK314688D0 (da) | Fremgangsmaader til forbedret maalsoegning med antistof, antistoffragmenter, hormoner og andre maalsoegningsmidler samt konjugater deraf | |
| Nakamura et al. | Effect of IFN-γ on the immune response in vivo and on gene expression in vitro | |
| CO4850562A1 (es) | Proceso para producir una preparacion concentrada de anticuerpos | |
| EG15882A (en) | Procede de preparation de nouveaux conjuges associants,par liaison covalente,une enzyme et un anticorps | |
| MD1374G2 (ro) | Anticorpi monoclonali imunostimulatori, procedeu de obţinere a acestora, linii celulare, metodă de tratare a maladiilor şi compoziţie farmaceutică | |
| ES2112838T3 (es) | Peptidos receptores de celulas t como agentes terapeuticos para enfermedades autoinmunitarias y malignas. | |
| NL300418I1 (nl) | Gebruik van trifunctionele bispecifieke en trispecifieke antilichamen voor de behandeling van maligne ascitis | |
| NZ508381A (en) | Antibodies, antagonists and agonists of the death domain containing receptor 5 (DR5) | |
| WO2002045653A3 (en) | Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody | |
| WO1999063945A3 (en) | Vaccination strategy to prevent and treat cancers | |
| TNSN93012A1 (fr) | Conception, clonage et expression d'anticorps monoclonaux humanises contre l'interleukine-5 humaine | |
| DK0910407T3 (da) | Fremgangsmåde og sammensætning til rekonformation af multiepitope antigener for at initiere et immunrespons | |
| AU2002223462A1 (en) | Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28 | |
| EP0368668A3 (en) | Antibody-drug conjugates | |
| ES2144418T3 (es) | Peptidos de receptores de celulas t como agentes terapeuticos para enfermedades relacionadas con el sistema inmunitario. | |
| MY103231A (en) | Immunoglobulin conjugates | |
| AU641736B2 (en) | Delivery of agents | |
| McGuigan | Binding of caerulein by antibodies to human gastrin I | |
| Vogt et al. | Functional identity of anaphylatoxin preparations obtained from different species and by different activation procedures. II. Immunological identity | |
| ES8802263A1 (es) | Procedimiento inmunologico para la determinacion de la hormona luteinizante | |
| Mikalauskene et al. | Preparation of monoclonal antibodies to gp51 antigen and their use for early diagnosis of bovine leukemia | |
| TANNO | Effect of moxibustion on blastoid transformation of rabbit peripheral lymphocytes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AHB | Application shelved due to non-payment |